Kadmon To Present At Two Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN), today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present an overview of the Company and its clinical programs at two upcoming investor conferences in New York:

• BioCentury 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 9:00 a.m. ET
• Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016, at 10:00 a.m. ET

Live audio webcasts of the presentations may be accessed from the “Presentations and Events” page within the Investors section of the Kadmon website at www.kadmon.com. Replays of the webcasts will be available for 90 days.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. Kadmon is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the SEC on July 27, 2016. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.